Clinical trials: PAH Gene Expression
Pulmonary Arterial Hypertension
The Expression and Significance of MiRNA
It is not always known what causes PAH or what the best treatment is. The doctors doing this study would like to understand more about why some people develop PAH and other do not.
- Trial name
- NCT00806312
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Megan Ballinger
Type 1 Diabetes Mellitus
The Effect of Uric Acid Lowering in Type 1 Diabetes
Patients with type 1 diabetes mellitus (T1DM) are at high risk of developing kidney complications potentially leading to end stage renal disease.
- Trial name
- NCT02344602
- Testing
- Febuxostat
- Where
- Canada
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Phenylketonuria, Behavior and Behavior Mechanisms
Evaluation of Behavior, Executive Function, Neurotransmitter Function and Genomic Expression Kuvan Nonresponders
This observational study seeks to establish evidence: 1. that physiologic changes, unrelated to effect on the Phenylalanine Hydroxylase (PAH) enzyme, occur in Phenylketonuria (PKU) patients who are treated with sapropterin…
- Conditions
- Phenylketonuria, Behavior and Behavior Mechanisms, PAH Gene Expression
- Trial name
- IST (NCT01274026)
- Testing
- sapropterin dihydrochloride
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Tulane University School of Medicine
Pulmonary Arterial Hypertension, Healthy
Quantifying 18kDa TSPO Expression in the Lung in Pulmonary Artery Hypertension (PAH)
The aim of this study is to determine whether there is an increase in the TSPO PET signal (measured with the radioligand [11C]PBR28) in the lungs of patients living with PAH relative to age matched controls.
- Trial name
- NCT05745961
- Testing
- TSPO PET scan (11C-PBR28)
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Imperial College London